ID   POL_HV1N5               Reviewed;        1435 AA.
AC   P12497;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   27-JUL-2011, sequence version 4.
DT   29-APR-2015, entry version 187.
DE   RecName: Full=Gag-Pol polyprotein;
DE   AltName: Full=Pr160Gag-Pol;
DE   Contains:
DE     RecName: Full=Matrix protein p17;
DE              Short=MA;
DE   Contains:
DE     RecName: Full=Capsid protein p24;
DE              Short=CA;
DE   Contains:
DE     RecName: Full=Spacer peptide 1 {ECO:0000303|PubMed:22334652};
DE              Short=SP1;
DE     AltName: Full=p2;
DE   Contains:
DE     RecName: Full=Nucleocapsid protein p7;
DE              Short=NC;
DE   Contains:
DE     RecName: Full=Transframe peptide;
DE              Short=TF;
DE   Contains:
DE     RecName: Full=p6-pol;
DE              Short=p6*;
DE   Contains:
DE     RecName: Full=Protease;
DE              EC=3.4.23.16;
DE     AltName: Full=PR;
DE     AltName: Full=Retropepsin;
DE   Contains:
DE     RecName: Full=Reverse transcriptase/ribonuclease H;
DE              EC=2.7.7.49;
DE              EC=2.7.7.7;
DE              EC=3.1.26.13;
DE     AltName: Full=Exoribonuclease H;
DE              EC=3.1.13.2;
DE     AltName: Full=p66 RT;
DE   Contains:
DE     RecName: Full=p51 RT;
DE   Contains:
DE     RecName: Full=p15;
DE   Contains:
DE     RecName: Full=Integrase;
DE              Short=IN;
GN   Name=gag-pol;
OS   Human immunodeficiency virus type 1 group M subtype B (isolate NY5)
OS   (HIV-1).
OC   Viruses; Retro-transcribing viruses; Retroviridae; Orthoretrovirinae;
OC   Lentivirus; Primate lentivirus group.
OX   NCBI_TaxID=11698;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Clone pNL4-3;
RA   Buckler C.E., Buckler-White A.J., Willey R.L., McCoy J.;
RL   Submitted (JUN-1988) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   SEQUENCE REVISION TO 545.
RA   Strebel K.J., Martin M.A.;
RL   Submitted (MAY-2010) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   INTERACTION OF MATRIX PROTEIN P17 WITH GP41.
RX   PubMed=8918455;
RA   Cosson P.;
RT   "Direct interaction between the envelope and matrix proteins of HIV-
RT   1.";
RL   EMBO J. 15:5783-5788(1996).
RN   [4]
RP   INTERACTION OF MATRIX PROTEIN P17 WITH HUMAN AP3D1.
RX   PubMed=15766529; DOI=10.1016/j.cell.2004.12.023;
RA   Dong X., Li H., Derdowski A., Ding L., Burnett A., Chen X.,
RA   Peters T.R., Dermody T.S., Woodruff E., Wang J.J., Spearman P.;
RT   "AP-3 directs the intracellular trafficking of HIV-1 Gag and plays a
RT   key role in particle assembly.";
RL   Cell 120:663-674(2005).
RN   [5]
RP   INTERACTION OF INTEGRASE WITH HUMAN NUP153.
RC   STRAIN=Clone pNL4-3;
RX   PubMed=19369352; DOI=10.1128/JVI.02061-08;
RA   Woodward C.L., Prakobwanakit S., Mosessian S., Chow S.A.;
RT   "Integrase interacts with nucleoporin NUP153 to mediate the nuclear
RT   import of human immunodeficiency virus type 1.";
RL   J. Virol. 83:6522-6533(2009).
RN   [6]
RP   MUTAGENESIS OF SER-9; SER-67; SER-72 AND SER-77.
RX   PubMed=19059618; DOI=10.1016/j.virol.2008.10.047;
RA   Bhatia A.K., Kaushik R., Campbell N.A., Pontow S.E., Ratner L.;
RT   "Mutation of critical serine residues in HIV-1 matrix result in an
RT   envelope incorporation defect which can be rescued by truncation of
RT   the gp41 cytoplasmic tail.";
RL   Virology 384:233-241(2009).
RN   [7]
RP   SUBCELLULAR LOCATION OF GAG-POL POLYPROTEIN.
RX   PubMed=19297499; DOI=10.1128/JVI.00109-09;
RA   Joshi A., Ablan S.D., Soheilian F., Nagashima K., Freed E.O.;
RT   "Evidence that productive human immunodeficiency virus type 1 assembly
RT   can occur in an intracellular compartment.";
RL   J. Virol. 83:5375-5387(2009).
RN   [8]
RP   INTERACTION OF MATRIX PROTEIN P17 WITH RAT CALM1.
RX   PubMed=21799007; DOI=10.1074/jbc.M111.273623;
RA   Samal A.B., Ghanam R.H., Fernandez T.F., Monroe E.B., Saad J.S.;
RT   "NMR, biophysical, and biochemical studies reveal the minimal
RT   Calmodulin binding domain of the HIV-1 matrix protein.";
RL   J. Biol. Chem. 286:33533-33543(2011).
RN   [9]
RP   PROTEOLYTIC PROCESSING OF POLYPROTEIN.
RX   PubMed=22334652; DOI=10.1074/jbc.M112.339374;
RA   Lee S.K., Potempa M., Kolli M., Ozen A., Schiffer C.A., Swanstrom R.;
RT   "Context surrounding processing sites is crucial in determining
RT   cleavage rate of a subset of processing sites in HIV-1 Gag and Gag-
RT   Pro-Pol polyprotein precursors by viral protease.";
RL   J. Biol. Chem. 287:13279-13290(2012).
RN   [10]
RP   INTERACTION OF CAPSID WITH HUMAN NUP153.
RC   STRAIN=Clone pNL4-3;
RX   PubMed=24130490; DOI=10.1371/journal.ppat.1003693;
RA   Matreyek K.A., Yucel S.S., Li X., Engelman A.;
RT   "Nucleoporin NUP153 phenylalanine-glycine motifs engage a common
RT   binding pocket within the HIV-1 capsid protein to mediate lentiviral
RT   infectivity.";
RL   PLoS Pathog. 9:E1003693-E1003693(2013).
RN   [11]
RP   SUBUNIT (CAPSID PROTEIN P24).
RX   PubMed=24066695; DOI=10.1021/ja406246z;
RA   Deshmukh L., Schwieters C.D., Grishaev A., Ghirlando R., Baber J.L.,
RA   Clore G.M.;
RT   "Structure and dynamics of full-length HIV-1 capsid protein in
RT   solution.";
RL   J. Am. Chem. Soc. 135:16133-16147(2013).
RN   [12]
RP   INTERACTION OF MATRIX PROTEIN P17 WITH RNA.
RX   PubMed=23552424; DOI=10.1128/JVI.00075-13;
RA   Chukkapalli V., Inlora J., Todd G.C., Ono A.;
RT   "Evidence in support of RNA-mediated inhibition of phosphatidylserine-
RT   dependent HIV-1 Gag membrane binding in cells.";
RL   J. Virol. 87:7155-7159(2013).
RN   [13]
RP   PHOSPHORYLATION AT SER-148 (CAPSID PROTEIN P24).
RX   PubMed=24509437; DOI=10.1099/vir.0.060053-0;
RA   Dochi T., Nakano T., Inoue M., Takamune N., Shoji S., Sano K.,
RA   Misumi S.;
RT   "Phosphorylation of human immunodeficiency virus type 1 capsid protein
RT   at serine 16, required for peptidyl-prolyl isomerase-dependent
RT   uncoating, is mediated by virion-incorporated extracellular signal-
RT   regulated kinase 2.";
RL   J. Gen. Virol. 95:1156-1166(2014).
RN   [14]
RP   REVIEW.
RX   PubMed=8791726;
RA   Vogt V.M.;
RT   "Proteolytic processing and particle maturation.";
RL   Curr. Top. Microbiol. Immunol. 214:95-131(1996).
RN   [15]
RP   REVIEW.
RX   PubMed=9878383; DOI=10.1006/jmbi.1998.2354;
RA   Turner B.G., Summers M.F.;
RT   "Structural biology of HIV.";
RL   J. Mol. Biol. 285:1-32(1999).
RN   [16]
RP   REVIEW.
RX   PubMed=11700285; DOI=10.1146/annurev.genet.35.102401.090551;
RA   Negroni M., Buc H.;
RT   "Mechanisms of retroviral recombination.";
RL   Annu. Rev. Genet. 35:275-302(2001).
RN   [17]
RP   REVIEW.
RX   PubMed=11983066; DOI=10.1186/gb-2002-3-4-reviews3006;
RA   Dunn B.M., Goodenow M.M., Gustchina A., Wlodawer A.;
RT   "Retroviral proteases.";
RL   Genome Biol. 3:REVIEWS3006.1-REVIEWS3006.7(2002).
RN   [18]
RP   REVIEW.
RX   PubMed=12873766; DOI=10.1016/S0005-2736(03)00163-9;
RA   Scarlata S., Carter C.;
RT   "Role of HIV-1 Gag domains in viral assembly.";
RL   Biochim. Biophys. Acta 1614:62-72(2003).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 489-587.
RX   PubMed=2645523; DOI=10.1038/337615a0;
RA   Navia M.A., Fitzgerald P.M.D., McKeever B.M., Leu C.-T.,
RA   Heimbach J.C., Herber W.K., Sigal I.S., Darke P.L., Springer J.P.;
RT   "Three-dimensional structure of aspartyl protease from human
RT   immunodeficiency virus HIV-1.";
RL   Nature 337:615-620(1989).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 489-587.
RX   PubMed=2548279; DOI=10.1126/science.2548279;
RA   Wlodawer A., Miller M., Jaskolski M., Sathyanarayana B.K., Baldwin E.,
RA   Weber I.T., Selk L.M., Clawson L., Schneider J., Kent S.B.H.;
RT   "Conserved folding in retroviral proteases: crystal structure of a
RT   synthetic HIV-1 protease.";
RL   Science 245:616-621(1989).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 489-587.
RX   PubMed=2201682;
RA   Fitzgerald P.M.D., McKeever B.M., van Middlesworth J.F.,
RA   Springer J.P., Heimbach J.C., Leu C.-T., Herber W.K., Dixon R.A.F.,
RA   Darke P.L.;
RT   "Crystallographic analysis of a complex between human immunodeficiency
RT   virus type 1 protease and acetyl-pepstatin at 2.0-A resolution.";
RL   J. Biol. Chem. 265:14209-14219(1990).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 489-587.
RX   PubMed=2200122; DOI=10.1126/science.2200122;
RA   Erickson J., Neidhart D.J., Vandrie J., Kempf D.J., Wang X.C.,
RA   Norbeck D.W., Plattner J.J., Rittenhouse J.W., Turon M.,
RA   Wideburg N.E., Kohlbrenner W.E., Simmer R., Helfrich R., Paul D.A.,
RA   Knigge M.;
RT   "Design, activity, and 2.8 A crystal structure of a C2 symmetric
RT   inhibitor complexed to HIV-1 protease.";
RL   Science 249:527-533(1990).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (3.7 ANGSTROMS) OF 133-283.
RX   PubMed=2123631; DOI=10.1089/aid.1990.6.1169;
RA   Ehrlich L.S., Krausslich H.G., Wimmer E., Carter C.A.;
RT   "Expression in Escherichia coli and purification of human
RT   immunodeficiency virus type 1 capsid protein (p24).";
RL   AIDS Res. Hum. Retroviruses 6:1169-1175(1990).
RN   [24]
RP   STRUCTURE BY NMR OF 1-132.
RX   PubMed=7966331; DOI=10.1006/jmbi.1994.1719;
RA   Massiah M.A., Starich M.R., Paschall C., Summers M.F.,
RA   Christensen A.M., Sundquist W.I.;
RT   "Three-dimensional structure of the human immunodeficiency virus type
RT   1 matrix protein.";
RL   J. Mol. Biol. 244:198-223(1994).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 501-599 IN COMPLEX WITH THE
RP   INHIBITOR L-736,524.
RX   PubMed=7929352;
RA   Chen Z., Li Y., Chen E., Hall D.L., Darke P.L., Culberson C.,
RA   Shafer J.A., Kuo L.C.;
RT   "Crystal structure at 1.9-A resolution of human immunodeficiency virus
RT   (HIV) II protease complexed with L-735,524, an orally bioavailable
RT   inhibitor of the HIV proteases.";
RL   J. Biol. Chem. 269:26344-26348(1994).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 1197-1359.
RX   PubMed=7801124; DOI=10.1126/science.7801124;
RA   Dyda F., Hickman A.B., Jenkins T.M., Engelman A., Craigie R.,
RA   Davies D.R.;
RT   "Crystal structure of the catalytic domain of HIV-1 integrase:
RT   similarity to other polynucleotidyl transferases.";
RL   Science 266:1981-1986(1994).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 1-132.
RX   PubMed=8610175; DOI=10.1073/pnas.93.7.3099;
RA   Hill C.P., Worthylake D.K., Bancroft D.P., Christensen A.M.,
RA   Sundquist W.I.;
RT   "Crystal structures of the trimeric human immunodeficiency virus type
RT   1 matrix protein: implications for membrane association and
RT   assembly.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:3099-3104(1996).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.36 ANGSTROMS) OF 133-277, AND INTERACTION OF
RP   CAPSID PROTEIN WITH HUMAN PPIA/CYPA.
RX   PubMed=8980234; DOI=10.1016/S0092-8674(00)81823-1;
RA   Gamble T.R., Vajdos F.F., Yoo S., Worthylake D.K., Houseweart M.,
RA   Sundquist W.I., Hill C.P.;
RT   "Crystal structure of human cyclophilin A bound to the amino-terminal
RT   domain of HIV-1 capsid.";
RL   Cell 87:1285-1294(1996).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 1197-1359, AND ACTIVE SITES
RP   OF INTEGRASE.
RX   PubMed=8977101; DOI=10.1016/S0014-5793(96)01236-7;
RA   Bujacz G., Alexandratos J., Qing Z.L., Clement-Mella C., Wlodawer A.;
RT   "The catalytic domain of human immunodeficiency virus integrase:
RT   ordered active site in the F185H mutant.";
RL   FEBS Lett. 398:175-178(1996).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 278-377.
RX   PubMed=9346481; DOI=10.1126/science.278.5339.849;
RA   Gamble T.R., Yoo S., Vajdos F.F., von Schwedler U.K., Worthylake D.K.,
RA   Wang H., McCutcheon J.P., Sundquist W.I., Hill C.P.;
RT   "Structure of the carboxyl-terminal dimerization domain of the HIV-1
RT   capsid protein.";
RL   Science 278:849-853(1997).
RN   [31]
RP   STRUCTURE BY NMR OF 1148-1202.
RX   PubMed=9228950; DOI=10.1038/nsb0797-567;
RA   Cai M., Zheng R., Caffrey M., Craigie R., Clore G.M., Gronenborn A.M.;
RT   "Solution structure of the N-terminal zinc binding domain of HIV-1
RT   integrase.";
RL   Nat. Struct. Biol. 4:567-577(1997).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 1197-1356.
RX   PubMed=9689049; DOI=10.1073/pnas.95.16.9150;
RA   Goldgur Y., Dyda F., Hickman A.B., Jenkins T.M., Craigie R.,
RA   Davies D.R.;
RT   "Three new structures of the core domain of HIV-1 integrase: an active
RT   site that binds magnesium.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:9150-9154(1998).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 1197-1359.
RX   PubMed=10413462; DOI=10.1021/bi9907173;
RA   Greenwald J., Le V., Butler S.L., Bushman F.D., Choe S.;
RT   "The mobility of an HIV-1 integrase active site loop is correlated
RT   with catalytic activity.";
RL   Biochemistry 38:8892-8898(1999).
RN   [34]
RP   STRUCTURE BY NMR OF 133-283.
RX   PubMed=12032547; DOI=10.1038/nsb806;
RA   Tang C., Ndassa Y., Summers M.F.;
RT   "Structure of the N-terminal 283-residue fragment of the immature HIV-
RT   1 Gag polyprotein.";
RL   Nat. Struct. Biol. 9:537-543(2002).
RN   [35]
RP   STRUCTURE BY NMR OF 1-132.
RX   PubMed=14699046; DOI=10.1073/pnas.0305665101;
RA   Tang C., Loeliger E., Luncsford P., Kinde I., Beckett D.,
RA   Summers M.F.;
RT   "Entropic switch regulates myristate exposure in the HIV-1 matrix
RT   protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:517-522(2004).
RN   [36]
RP   STRUCTURE BY NMR OF 2-132, INTERACTION OF MATRIX PROTEIN P17 WITH
RP   PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE, AND FUNCTION (MATRIX PROTEIN
RP   P17).
RX   PubMed=16840558; DOI=10.1073/pnas.0602818103;
RA   Saad J.S., Miller J., Tai J., Kim A., Ghanam R.H., Summers M.F.;
RT   "Structural basis for targeting HIV-1 Gag proteins to the plasma
RT   membrane for virus assembly.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:11364-11369(2006).
CC   -!- FUNCTION: Gag-Pol polyprotein: Mediates, with Gag polyrotein, the
CC       essential events in virion assembly, including binding the plasma
CC       membrane, making the protein-protein interactions necessary to
CC       create spherical particles, recruiting the viral Env proteins, and
CC       packaging the genomic RNA via direct interactions with the RNA
CC       packaging sequence (Psi). Gag-Pol polyprotein may regulate its own
CC       translation, by the binding genomic RNA in the 5'-UTR. At low
CC       concentration, the polyprotein would promote translation, whereas
CC       at high concentration, the polyprotein would encapsidate genomic
CC       RNA and then shutt off translation. {ECO:0000250}.
CC   -!- FUNCTION: Matrix protein p17: Targets the polyprotein to the
CC       plasma membrane via a multipartite membrane-binding signal, that
CC       includes its myristoylated N-terminus (PubMed:16840558). Matrix
CC       protein is part of the pre-integration complex. Implicated in the
CC       release from host cell mediated by Vpu. Binds to RNA.
CC       {ECO:0000250, ECO:0000269|PubMed:16840558,
CC       ECO:0000269|PubMed:23552424}.
CC   -!- FUNCTION: Capsid protein p24: Forms the conical core that
CC       encapsulates the genomic RNA-nucleocapsid complex in the virion.
CC       Most core are conical, with only 7% tubular. The core is
CC       constituted by capsid protein hexamer subunits. The core is
CC       disassembled soon after virion entry (By similarity). Host
CC       restriction factors such as TRIM5-alpha or TRIMCyp bind retroviral
CC       capsids and cause premature capsid disassembly, leading to blocks
CC       in reverse transcription. Capsid restriction by TRIM5 is one of
CC       the factors which restricts HIV-1 to the human species. Host PIN1
CC       apparently facilitates the virion uncoating (PubMed:24509437). On
CC       the other hand, interactions with PDZD8 or CYPA stabilize the
CC       capsid. {ECO:0000250|UniProtKB:P04585,
CC       ECO:0000269|PubMed:24509437}.
CC   -!- FUNCTION: Nucleocapsid protein p7: Encapsulates and protects viral
CC       dimeric unspliced genomic RNA (gRNA). Binds these RNAs through its
CC       zinc fingers. Acts as a nucleic acid chaperone which is involved
CC       in rearangement of nucleic acid secondary structure during gRNA
CC       retrotranscription. Also facilitates template switch leading to
CC       recombination. As part of the polyprotein, participates to gRNA
CC       dimerization, packaging, tRNA incorporation and virion assembly.
CC       {ECO:0000250|UniProtKB:P04585}.
CC   -!- FUNCTION: Protease: Aspartyl protease that mediates proteolytic
CC       cleavages of Gag and Gag-Pol polyproteins during or shortly after
CC       the release of the virion from the plasma membrane. Cleavages take
CC       place as an ordered, step-wise cascade to yield mature proteins.
CC       This process is called maturation. Displays maximal activity
CC       during the budding process just prior to particle release from the
CC       cell. Also cleaves Nef and Vif, probably concomitantly with viral
CC       structural proteins on maturation of virus particles. Hydrolyzes
CC       host EIF4GI and PABP1 in order to shut off the capped cellular
CC       mRNA translation. The resulting inhibition of cellular protein
CC       synthesis serves to ensure maximal viral gene expression and to
CC       evade host immune response (By similarity).
CC       {ECO:0000250|UniProtKB:P04585, ECO:0000255|PROSITE-
CC       ProRule:PRU00275}.
CC   -!- FUNCTION: Reverse transcriptase/ribonuclease H: Multifunctional
CC       enzyme that converts the viral RNA genome into dsDNA in the
CC       cytoplasm, shortly after virus entry into the cell. This enzyme
CC       displays a DNA polymerase activity that can copy either DNA or RNA
CC       templates, and a ribonuclease H (RNase H) activity that cleaves
CC       the RNA strand of RNA-DNA heteroduplexes in a partially processive
CC       3' to 5' endonucleasic mode. Conversion of viral genomic RNA into
CC       dsDNA requires many steps. A tRNA(3)-Lys binds to the primer-
CC       binding site (PBS) situated at the 5'-end of the viral RNA. RT
CC       uses the 3' end of the tRNA primer to perform a short round of
CC       RNA-dependent minus-strand DNA synthesis. The reading proceeds
CC       through the U5 region and ends after the repeated (R) region which
CC       is present at both ends of viral RNA. The portion of the RNA-DNA
CC       heteroduplex is digested by the RNase H, resulting in a ssDNA
CC       product attached to the tRNA primer. This ssDNA/tRNA hybridizes
CC       with the identical R region situated at the 3' end of viral RNA.
CC       This template exchange, known as minus-strand DNA strong stop
CC       transfer, can be either intra- or intermolecular. RT uses the 3'
CC       end of this newly synthesized short ssDNA to perform the RNA-
CC       dependent minus-strand DNA synthesis of the whole template. RNase
CC       H digests the RNA template except for two polypurine tracts (PPTs)
CC       situated at the 5'-end and near the center of the genome. It is
CC       not clear if both polymerase and RNase H activities are
CC       simultaneous. RNase H probably can proceed both in a polymerase-
CC       dependent (RNA cut into small fragments by the same RT performing
CC       DNA synthesis) and a polymerase-independent mode (cleavage of
CC       remaining RNA fragments by free RTs). Secondly, RT performs DNA-
CC       directed plus-strand DNA synthesis using the PPTs that have not
CC       been removed by RNase H as primers. PPTs and tRNA primers are then
CC       removed by RNase H. The 3' and 5' ssDNA PBS regions hybridize to
CC       form a circular dsDNA intermediate. Strand displacement synthesis
CC       by RT to the PBS and PPT ends produces a blunt ended, linear dsDNA
CC       copy of the viral genome that includes long terminal repeats
CC       (LTRs) at both ends. {ECO:0000250|UniProtKB:P04585}.
CC   -!- FUNCTION: Integrase: Catalyzes viral DNA integration into the host
CC       chromosome, by performing a series of DNA cutting and joining
CC       reactions. This enzyme activity takes place after virion entry
CC       into a cell and reverse transcription of the RNA genome in dsDNA.
CC       The first step in the integration process is 3' processing. This
CC       step requires a complex comprising the viral genome, matrix
CC       protein, Vpr and integrase. This complex is called the pre-
CC       integration complex (PIC). The integrase protein removes 2
CC       nucleotides from each 3' end of the viral DNA, leaving recessed CA
CC       OH's at the 3' ends. In the second step, the PIC enters cell
CC       nucleus. This process is mediated through integrase and Vpr
CC       proteins, and allows the virus to infect a non dividing cell. This
CC       ability to enter the nucleus is specific of lentiviruses, other
CC       retroviruses cannot and rely on cell division to access cell
CC       chromosomes. In the third step, termed strand transfer, the
CC       integrase protein joins the previously processed 3' ends to the 5'
CC       ends of strands of target cellular DNA at the site of integration.
CC       The 5'-ends are produced by integrase-catalyzed staggered cuts, 5
CC       bp apart. A Y-shaped, gapped, recombination intermediate results,
CC       with the 5'-ends of the viral DNA strands and the 3' ends of
CC       target DNA strands remaining unjoined, flanking a gap of 5 bp. The
CC       last step is viral DNA integration into host chromosome. This
CC       involves host DNA repair synthesis in which the 5 bp gaps between
CC       the unjoined strands are filled in and then ligated. Since this
CC       process occurs at both cuts flanking the HIV genome, a 5 bp
CC       duplication of host DNA is produced at the ends of HIV-1
CC       integration. Alternatively, Integrase may catalyze the excision of
CC       viral DNA just after strand transfer, this is termed
CC       disintegration. {ECO:0000250|UniProtKB:P04585}.
CC   -!- CATALYTIC ACTIVITY: Specific for a P1 residue that is hydrophobic,
CC       and P1' variable, but often Pro. {ECO:0000255|PROSITE-
CC       ProRule:PRU00275}.
CC   -!- CATALYTIC ACTIVITY: Endohydrolysis of RNA in RNA/DNA hybrids.
CC       Three different cleavage modes: 1. sequence-specific internal
CC       cleavage of RNA. Human immunodeficiency virus type 1 and Moloney
CC       murine leukemia virus enzymes prefer to cleave the RNA strand one
CC       nucleotide away from the RNA-DNA junction. 2. RNA 5'-end directed
CC       cleavage 13-19 nucleotides from the RNA end. 3. DNA 3'-end
CC       directed cleavage 15-20 nucleotides away from the primer terminus.
CC       {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: 3'-end directed exonucleolytic cleavage of
CC       viral RNA-DNA hybrid. {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: Deoxynucleoside triphosphate + DNA(n) =
CC       diphosphate + DNA(n+1). {ECO:0000255|PROSITE-ProRule:PRU00405}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Note=Binds 2 magnesium ions for reverse transcriptase polymerase
CC       activity. {ECO:0000250};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Note=Binds 2 magnesium ions for ribonuclease H (RNase H) activity.
CC       Substrate-binding is a precondition for magnesium binding.
CC       {ECO:0000250};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Note=Magnesium ions are required for integrase activity. Binds at
CC       least 1, maybe 2 magnesium ions. {ECO:0000250};
CC   -!- ENZYME REGULATION: Protease: The viral protease is inhibited by
CC       many synthetic protease inhibitors (PIs), such as amprenavir,
CC       atazanavir, indinavir, loprinavir, nelfinavir, ritonavir and
CC       saquinavir. Use of protease inhibitors in tritherapy regimens
CC       permit more ambitious therapeutic strategies. Reverse
CC       transcriptase/ribonuclease H: RT can be inhibited either by
CC       nucleoside RT inhibitors (NRTIs) or by non nucleoside RT
CC       inhibitors (NNRTIs). NRTIs act as chain terminators, whereas
CC       NNRTIs inhibit DNA polymerization by binding a small hydrophobic
CC       pocket near the RT active site and inducing an allosteric change
CC       in this region. Classical NRTIs are abacavir, adefovir (PMEA),
CC       didanosine (ddI), lamivudine (3TC), stavudine (d4T), tenofovir
CC       (PMPA), zalcitabine (ddC), and zidovudine (AZT). Classical NNRTIs
CC       are atevirdine (BHAP U-87201E), delavirdine, efavirenz (DMP-266),
CC       emivirine (I-EBU), and nevirapine (BI-RG-587). The tritherapies
CC       used as a basic effective treatment of AIDS associate two NRTIs
CC       and one NNRTI. {ECO:0000250}.
CC   -!- SUBUNIT: Matrix protein p17: Homotrimer; further assembles as
CC       hexamers of trimers (By similarity). Matrix protein p17: Interacts
CC       with gp41 (via C-terminus) (By similarity). Matrix protein p17:
CC       interacts with host CALM1; this interaction induces a
CC       conformational change in the Matrix protein, triggering exposure
CC       of the myristate group (By similarity). Matrix protein p17:
CC       interacts with host AP3D1; this interaction allows the polyprotein
CC       trafficking to multivesicular bodies during virus assembly (By
CC       similarity). Matrix protein p17: Part of the pre-integration
CC       complex (PIC) which is composed of viral genome, matrix protein,
CC       Vpr and integrase (By similarity). Capsid protein p24: Homodimer;
CC       the homodimer further multimerizes as homohexamers or
CC       homopentamers. Capsid protein p24: Interacts with human PPIA/CYPA
CC       (By similarity); This interaction stabilizes the capsid. Capsid
CC       protein p24: Interacts with human NUP153 (By similarity). Capsid
CC       protein p24: Interacts with host PDZD8; this interaction
CC       stabilizes the capsid (By similarity). Capsid protein p24:
CC       Interacts with monkey TRIM5; this interaction destabilizes the
CC       capsid (By similarity).Protease: Homodimer, whose active site
CC       consists of two apposed aspartic acid residues. Reverse
CC       transcriptase/ribonuclease H: Heterodimer of p66 RT and p51 RT (RT
CC       p66/p51). Heterodimerization of RT is essential for DNA polymerase
CC       activity. Despite the sequence identities, p66 RT and p51 RT have
CC       distinct folding. Integrase: Homodimer; possibly can form
CC       homotetramer. Integrase: Part of the pre-integration complex (PIC)
CC       which is composed of viral genome, matrix protein, Vpr and
CC       integrase. Integrase: Interacts with human SMARCB1/INI1 and human
CC       PSIP1/LEDGF isoform 1. Integrase: Interacts with human KPNA3; this
CC       interaction might play a role in nuclear import of the pre-
CC       integration complex (By similarity). Integrase: Interacts with
CC       human NUP153; this interaction might play a role in nuclear import
CC       of the pre-integration complex (By similarity).
CC       {ECO:0000250|UniProtKB:P04585}.
CC   -!- INTERACTION:
CC       O75475-1:PSIP1 (xeno); NbExp=3; IntAct=EBI-10131955, EBI-5279836;
CC   -!- SUBCELLULAR LOCATION: Gag-Pol polyprotein: Host cell membrane;
CC       Lipid-anchor {ECO:0000269|PubMed:19297499}. Host endosome, host
CC       multivesicular body {ECO:0000269|PubMed:19297499}. Note=These
CC       locations are linked to virus assembly sites. The main location is
CC       the cell membrane, but under some circumstances, late endosomal
CC       compartments can serve as productive sites for virion assembly.
CC       {ECO:0000269|PubMed:19297499}.
CC   -!- SUBCELLULAR LOCATION: Matrix protein p17: Virion membrane; Lipid-
CC       anchor {ECO:0000305}. Host nucleus {ECO:0000250}. Host cytoplasm
CC       {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Capsid protein p24: Virion {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Nucleocapsid protein p7: Virion
CC       {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Reverse transcriptase/ribonuclease H: Virion
CC       {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Integrase: Virion {ECO:0000305}. Host
CC       nucleus {ECO:0000305}. Host cytoplasm {ECO:0000305}. Note=Nuclear
CC       at initial phase, cytoplasmic at assembly. {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Ribosomal frameshifting; Named isoforms=2;
CC         Comment=Translation results in the formation of the Gag
CC         polyprotein most of the time. Ribosomal frameshifting at the
CC         gag-pol genes boundary occurs at low frequency and produces the
CC         Gag-Pol polyprotein. This strategy of translation probably
CC         allows the virus to modulate the quantity of each viral protein.
CC         Maintenance of a correct Gag to Gag-Pol ratio is essential for
CC         RNA dimerization and viral infectivity.;
CC       Name=Gag-Pol polyprotein;
CC         IsoId=P12497-1; Sequence=Displayed;
CC         Note=Produced by -1 ribosomal frameshifting.;
CC       Name=Gag polyprotein;
CC         IsoId=P12493-1; Sequence=External;
CC         Note=Produced by conventional translation.;
CC   -!- DOMAIN: Reverse transcriptase/ribonuclease H: RT is structured in
CC       five subdomains: finger, palm, thumb, connection and RNase H.
CC       Within the palm subdomain, the 'primer grip' region is thought to
CC       be involved in the positioning of the primer terminus for
CC       accommodating the incoming nucleotide. The RNase H domain
CC       stabilizes the association of RT with primer-template.
CC       {ECO:0000250}.
CC   -!- DOMAIN: Reverse transcriptase/ribonuclease H: The tryptophan
CC       repeat motif is involved in RT p66/p51 dimerization (By
CC       similarity). {ECO:0000250}.
CC   -!- DOMAIN: Integrase: The core domain contains the D-x(n)-D-x(35)-E
CC       motif, named for the phylogenetically conserved glutamic acid and
CC       aspartic acid residues and the invariant 35 amino acid spacing
CC       between the second and third acidic residues. Each acidic residue
CC       of the D,D(35)E motif is independently essential for the 3'-
CC       processing and strand transfer activities of purified integrase
CC       protein. {ECO:0000250}.
CC   -!- PTM: Gag-Pol polyprotein: Specific enzymatic cleavages by the
CC       viral protease yield mature proteins. The protease is released by
CC       autocatalytic cleavage. The polyprotein is cleaved during and
CC       after budding, this process is termed maturation. Proteolytic
CC       cleavage of p66 RT removes the RNase H domain to yield the p51 RT
CC       subunit. Nucleocapsid protein p7 might be further cleaved after
CC       virus entry. {ECO:0000255|PROSITE-ProRule:PRU00405,
CC       ECO:0000269|PubMed:22334652}.
CC   -!- PTM: Matrix protein p17: Tyrosine phosphorylated presumably in the
CC       virion by a host kinase. Phosphorylation is apparently not a major
CC       regulator of membrane association. {ECO:0000250|UniProtKB:P04585}.
CC   -!- PTM: Capsid protein p24: Phosphorylated possibly by host MAPK1;
CC       this phosphorylation is necessary for Pin1-mediated virion
CC       uncoating. {ECO:0000269|PubMed:24509437}.
CC   -!- PTM: Nucleocapsid protein p7: Methylated by host PRMT6, impairing
CC       its function by reducing RNA annealing and the initiation of
CC       reverse transcription. {ECO:0000250|UniProtKB:P03347}.
CC   -!- MISCELLANEOUS: Reverse transcriptase/ribonuclease H: Error-prone
CC       enzyme that lacks a proof-reading function. High mutations rate is
CC       a direct consequence of this characteristic. RT also displays
CC       frequent template switching leading to high recombination rate.
CC       Recombination mostly occurs between homologous regions of the two
CC       copackaged RNA genomes. If these two RNA molecules derive from
CC       different viral strains, reverse transcription will give rise to
CC       highly recombinated proviral DNAs. {ECO:0000250}.
CC   -!- MISCELLANEOUS: HIV-1 lineages are divided in three main groups, M
CC       (for Major), O (for Outlier), and N (for New, or Non-M, Non-O).
CC       The vast majority of strains found worldwide belong to the group
CC       M. Group O seems to be endemic to and largely confined to Cameroon
CC       and neighboring countries in West Central Africa, where these
CC       viruses represent a small minority of HIV-1 strains. The group N
CC       is represented by a limited number of isolates from Cameroonian
CC       persons. The group M is further subdivided in 9 clades or subtypes
CC       (A to D, F to H, J and K). {ECO:0000250}.
CC   -!- MISCELLANEOUS: Resistance to inhibitors associated with mutations
CC       are observed both in viral protease and in reverse transcriptase.
CC       Most of the time, single mutations confer only a modest reduction
CC       in drug susceptibility. Combination of several mutations is
CC       usually required to develop a high-level drug resistance. These
CC       mutations are predominantly found in clade B viruses and not in
CC       other genotypes. They are listed in the clade B representative
CC       isolate HXB2 (AC P04585). {ECO:0000250}.
CC   -!- SIMILARITY: Contains 2 CCHC-type zinc fingers.
CC       {ECO:0000255|PROSITE-ProRule:PRU00047}.
CC   -!- SIMILARITY: Contains 1 integrase catalytic domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00457}.
CC   -!- SIMILARITY: Contains 1 integrase-type DNA-binding domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00506}.
CC   -!- SIMILARITY: Contains 1 integrase-type zinc finger.
CC       {ECO:0000255|PROSITE-ProRule:PRU00450}.
CC   -!- SIMILARITY: Contains 1 peptidase A2 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00275}.
CC   -!- SIMILARITY: Contains 1 reverse transcriptase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00405}.
CC   -!- SIMILARITY: Contains 1 RNase H domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00408}.
CC   -!- WEB RESOURCE: Name=HIV drug resistance mutations;
CC       URL="https://www.iasusa.org/content/hiv-drug-resistance-mutations";
CC   -!- WEB RESOURCE: Name=hivdb; Note=HIV drug resistance database;
CC       URL="http://hivdb.stanford.edu";
CC   -!- WEB RESOURCE: Name=BioAfrica: HIV bioinformatics in Africa;
CC       URL="http://www.bioafrica.net/index.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M19921; AAA44988.2; ALT_SEQ; Genomic_RNA.
DR   PDB; 1A43; X-ray; 2.60 A; A=278-363.
DR   PDB; 1A8O; X-ray; 1.70 A; A=284-352.
DR   PDB; 1AFV; X-ray; 3.70 A; A/B=133-283.
DR   PDB; 1AK4; X-ray; 2.36 A; C/D=133-277.
DR   PDB; 1AUM; X-ray; 3.00 A; A=283-352.
DR   PDB; 1B92; X-ray; 2.02 A; A=1197-1359.
DR   PDB; 1B9D; X-ray; 1.70 A; A=1197-1359.
DR   PDB; 1B9F; X-ray; 1.70 A; A=1197-1359.
DR   PDB; 1BAJ; X-ray; 2.60 A; A=278-377.
DR   PDB; 1BHL; X-ray; 2.20 A; A=1204-1354.
DR   PDB; 1BI4; X-ray; 2.50 A; A/B/C=1197-1356.
DR   PDB; 1BIS; X-ray; 1.95 A; A/B=1194-1356.
DR   PDB; 1BIU; X-ray; 2.50 A; A/B/C=1194-1359.
DR   PDB; 1BIZ; X-ray; 1.95 A; A/B=1197-1359.
DR   PDB; 1BL3; X-ray; 2.00 A; A/B/C=1197-1356.
DR   PDB; 1GWP; NMR; -; A=133-283.
DR   PDB; 1HIW; X-ray; 2.30 A; A/B/C/Q/R/S=1-132.
DR   PDB; 1HYV; X-ray; 1.70 A; A=1194-1359.
DR   PDB; 1HYZ; X-ray; 2.30 A; A=1194-1359.
DR   PDB; 1ITG; X-ray; 2.30 A; A=1194-1359.
DR   PDB; 1K6Y; X-ray; 2.40 A; A/B/C/D=1148-1359.
DR   PDB; 1M9D; X-ray; 1.90 A; C/D=133-278.
DR   PDB; 1QS4; X-ray; 2.10 A; A/B/C=1203-1356.
DR   PDB; 1UPH; NMR; -; A=2-132.
DR   PDB; 1WJB; NMR; -; A/B=1148-1202.
DR   PDB; 1WJD; NMR; -; A/B=1148-1202.
DR   PDB; 1WKN; Model; -; A/B=1148-1417.
DR   PDB; 1ZA9; Model; -; A/D/H/K=1148-1194, B/E/I/L=1197-1356, C/F/J/M=1367-1417.
DR   PDB; 2B4J; X-ray; 2.02 A; A/B=1197-1359.
DR   PDB; 2GOL; X-ray; 2.20 A; A=2-131, B/D=133-277.
DR   PDB; 2GON; X-ray; 1.90 A; A/B/C/D=133-278.
DR   PDB; 2H3F; NMR; -; A=2-132.
DR   PDB; 2H3I; NMR; -; A=2-132.
DR   PDB; 2H3Q; NMR; -; A=2-132.
DR   PDB; 2H3V; NMR; -; A=2-132.
DR   PDB; 2H3Z; NMR; -; A=2-132.
DR   PDB; 2HMX; NMR; -; A=1-132.
DR   PDB; 2HVP; X-ray; 3.00 A; A=489-587.
DR   PDB; 2ITG; X-ray; 2.60 A; A=1197-1359.
DR   PDB; 2JPR; NMR; -; A=133-277.
DR   PDB; 2JYG; NMR; -; A=280-363.
DR   PDB; 2JYL; NMR; -; A=280-363.
DR   PDB; 2LF4; NMR; -; A=133-363.
DR   PDB; 2LYA; NMR; -; A=2-132.
DR   PDB; 2LYB; NMR; -; A=2-132.
DR   PDB; 2M3Z; NMR; -; A=378-432.
DR   PDB; 2M8L; NMR; -; A/B=133-353.
DR   PDB; 2M8N; NMR; -; A=133-353.
DR   PDB; 2M8P; NMR; -; A=133-353.
DR   PDB; 2ONT; X-ray; 2.40 A; A=278-352.
DR   PDB; 2PWM; X-ray; 1.90 A; A/B/C/D/E/F/G/H=133-278.
DR   PDB; 2PWO; X-ray; 1.45 A; A/B/C/D=133-278.
DR   PDB; 2PXR; X-ray; 1.50 A; C=133-278.
DR   PDB; 2X2D; X-ray; 1.95 A; D/E=133-278.
DR   PDB; 2XDE; X-ray; 1.40 A; A/B=133-278.
DR   PDB; 2XV6; X-ray; 1.89 A; A/C=278-352.
DR   PDB; 2XXM; X-ray; 1.65 A; A=278-352.
DR   PDB; 3AV9; X-ray; 1.70 A; A/B=1197-1359.
DR   PDB; 3AVA; X-ray; 1.70 A; A/B=1197-1359.
DR   PDB; 3AVB; X-ray; 1.85 A; A/B=1197-1359.
DR   PDB; 3AVC; X-ray; 1.77 A; A/B=1197-1359.
DR   PDB; 3AVF; X-ray; 1.70 A; A/B=1197-1356.
DR   PDB; 3AVG; X-ray; 1.70 A; A/B=1197-1359.
DR   PDB; 3AVH; X-ray; 1.88 A; A/B=1197-1359.
DR   PDB; 3AVJ; X-ray; 1.70 A; A/B=1197-1359.
DR   PDB; 3AVK; X-ray; 1.75 A; A/B=1197-1359.
DR   PDB; 3AVL; X-ray; 1.88 A; A/B=1197-1359.
DR   PDB; 3AVM; X-ray; 1.88 A; A/B=1197-1359.
DR   PDB; 3AVN; X-ray; 2.10 A; A/B=1197-1359.
DR   PDB; 3DIK; EM; 9.00 A; A=133-351.
DR   PDB; 3DPH; X-ray; 2.01 A; A/B=278-363.
DR   PDB; 3DS0; X-ray; 1.60 A; A=278-363.
DR   PDB; 3DS1; X-ray; 1.60 A; A=278-363.
DR   PDB; 3DS2; X-ray; 1.20 A; A/B=278-363.
DR   PDB; 3DS3; X-ray; 2.70 A; A/B=278-363.
DR   PDB; 3DS4; X-ray; 1.12 A; A/B=278-363.
DR   PDB; 3DS5; X-ray; 2.40 A; A/B/C/D=278-363.
DR   PDB; 3DTJ; X-ray; 4.00 A; A/B/C/D=278-363.
DR   PDB; 3GV2; X-ray; 7.00 A; A/B/C/D/E/F=133-355.
DR   PDB; 3H47; X-ray; 1.90 A; A=133-363.
DR   PDB; 3H4E; X-ray; 2.70 A; A/B/C/D/E/F/G/H/I/J/K/L=133-363.
DR   PDB; 3L3U; X-ray; 1.40 A; A/B=1197-1359.
DR   PDB; 3L3V; X-ray; 2.00 A; A/B=1197-1359.
DR   PDB; 3LPT; X-ray; 2.00 A; A=1197-1359.
DR   PDB; 3LPU; X-ray; 1.95 A; A=1197-1359.
DR   PDB; 3LRY; X-ray; 1.98 A; A/B=278-363.
DR   PDB; 3MGE; X-ray; 1.90 A; A=133-363.
DR   PDB; 3NF6; X-ray; 1.90 A; A/B=1197-1359.
DR   PDB; 3NF7; X-ray; 1.80 A; A/B=1197-1359.
DR   PDB; 3NF8; X-ray; 1.90 A; A/B=1197-1359.
DR   PDB; 3NF9; X-ray; 1.95 A; A/B=1197-1359.
DR   PDB; 3NFA; X-ray; 1.95 A; A/B=1197-1359.
DR   PDB; 3P05; X-ray; 2.50 A; A/B/C/D/E=133-363.
DR   PDB; 3P0A; X-ray; 5.95 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T=133-363.
DR   PDB; 3S85; X-ray; 2.80 A; A/B/C/D/E/F/G/H/I/J/K/L=489-587.
DR   PDB; 3WNE; X-ray; 1.70 A; A/B=1203-1359.
DR   PDB; 3WNF; X-ray; 1.45 A; A/B=1203-1359.
DR   PDB; 3WNG; X-ray; 1.75 A; A/B=1203-1359.
DR   PDB; 3WNH; X-ray; 1.50 A; A/B=1203-1359.
DR   PDB; 4AH9; X-ray; 1.70 A; A/B=1197-1359.
DR   PDB; 4AHR; X-ray; 1.90 A; A/B=1197-1359.
DR   PDB; 4AHS; X-ray; 1.75 A; A/B=1197-1359.
DR   PDB; 4AHT; X-ray; 1.80 A; A/B=1197-1359.
DR   PDB; 4AHU; X-ray; 1.90 A; A/B=1197-1359.
DR   PDB; 4AHV; X-ray; 1.80 A; A/B=1197-1359.
DR   PDB; 4COC; X-ray; 1.59 A; A/B/C=278-363.
DR   PDB; 4COP; X-ray; 1.85 A; A/B=278-363.
DR   PDB; 4DGA; X-ray; 1.90 A; C/D=133-277.
DR   PDB; 4DGE; X-ray; 2.20 A; C/D=133-277.
DR   PDB; 4DMN; X-ray; 2.45 A; A=1197-1359.
DR   PDB; 4E1M; X-ray; 1.90 A; A=1197-1359.
DR   PDB; 4E1N; X-ray; 2.00 A; A=1197-1359.
DR   PDB; 4E91; X-ray; 1.70 A; A/B=133-278.
DR   PDB; 4E92; X-ray; 1.80 A; A/B=133-278.
DR   PDB; 4GVM; X-ray; 2.16 A; A=1197-1359.
DR   PDB; 4GW6; X-ray; 2.65 A; A=1197-1359.
DR   PDB; 4ID1; X-ray; 1.87 A; A=1197-1359.
DR   PDB; 4IPY; X-ray; 1.64 A; A/B/C/D=278-363.
DR   PDB; 4JLH; X-ray; 2.09 A; A=1197-1359.
DR   PDB; 4JMU; X-ray; 2.00 A; A=1-111.
DR   PDB; 4LQW; X-ray; 1.95 A; C/D=133-278.
DR   PDB; 4NX4; X-ray; 1.50 A; C=133-278.
DR   PDB; 4O0J; X-ray; 2.05 A; A=1197-1359.
DR   PDB; 4O55; X-ray; 2.24 A; A=1197-1359.
DR   PDB; 4O5B; X-ray; 2.37 A; A=1197-1359.
DR   PDB; 4PHV; X-ray; 2.10 A; A/B=489-587.
DR   PDB; 4QNB; X-ray; 2.00 A; A=133-363.
DR   PDB; 4WYM; X-ray; 2.60 A; A/B/C/D/E/F/G/H/I/J/K/L=133-363.
DR   PDB; 5HVP; X-ray; 2.00 A; A/B=489-587.
DR   PDB; 9HVP; X-ray; 2.80 A; A/B=489-587.
DR   PDBsum; 1A43; -.
DR   PDBsum; 1A8O; -.
DR   PDBsum; 1AFV; -.
DR   PDBsum; 1AK4; -.
DR   PDBsum; 1AUM; -.
DR   PDBsum; 1B92; -.
DR   PDBsum; 1B9D; -.
DR   PDBsum; 1B9F; -.
DR   PDBsum; 1BAJ; -.
DR   PDBsum; 1BHL; -.
DR   PDBsum; 1BI4; -.
DR   PDBsum; 1BIS; -.
DR   PDBsum; 1BIU; -.
DR   PDBsum; 1BIZ; -.
DR   PDBsum; 1BL3; -.
DR   PDBsum; 1GWP; -.
DR   PDBsum; 1HIW; -.
DR   PDBsum; 1HYV; -.
DR   PDBsum; 1HYZ; -.
DR   PDBsum; 1ITG; -.
DR   PDBsum; 1K6Y; -.
DR   PDBsum; 1M9D; -.
DR   PDBsum; 1QS4; -.
DR   PDBsum; 1UPH; -.
DR   PDBsum; 1WJB; -.
DR   PDBsum; 1WJD; -.
DR   PDBsum; 1WKN; -.
DR   PDBsum; 1ZA9; -.
DR   PDBsum; 2B4J; -.
DR   PDBsum; 2GOL; -.
DR   PDBsum; 2GON; -.
DR   PDBsum; 2H3F; -.
DR   PDBsum; 2H3I; -.
DR   PDBsum; 2H3Q; -.
DR   PDBsum; 2H3V; -.
DR   PDBsum; 2H3Z; -.
DR   PDBsum; 2HMX; -.
DR   PDBsum; 2HVP; -.
DR   PDBsum; 2ITG; -.
DR   PDBsum; 2JPR; -.
DR   PDBsum; 2JYG; -.
DR   PDBsum; 2JYL; -.
DR   PDBsum; 2LF4; -.
DR   PDBsum; 2LYA; -.
DR   PDBsum; 2LYB; -.
DR   PDBsum; 2M3Z; -.
DR   PDBsum; 2M8L; -.
DR   PDBsum; 2M8N; -.
DR   PDBsum; 2M8P; -.
DR   PDBsum; 2ONT; -.
DR   PDBsum; 2PWM; -.
DR   PDBsum; 2PWO; -.
DR   PDBsum; 2PXR; -.
DR   PDBsum; 2X2D; -.
DR   PDBsum; 2XDE; -.
DR   PDBsum; 2XV6; -.
DR   PDBsum; 2XXM; -.
DR   PDBsum; 3AV9; -.
DR   PDBsum; 3AVA; -.
DR   PDBsum; 3AVB; -.
DR   PDBsum; 3AVC; -.
DR   PDBsum; 3AVF; -.
DR   PDBsum; 3AVG; -.
DR   PDBsum; 3AVH; -.
DR   PDBsum; 3AVJ; -.
DR   PDBsum; 3AVK; -.
DR   PDBsum; 3AVL; -.
DR   PDBsum; 3AVM; -.
DR   PDBsum; 3AVN; -.
DR   PDBsum; 3DIK; -.
DR   PDBsum; 3DPH; -.
DR   PDBsum; 3DS0; -.
DR   PDBsum; 3DS1; -.
DR   PDBsum; 3DS2; -.
DR   PDBsum; 3DS3; -.
DR   PDBsum; 3DS4; -.
DR   PDBsum; 3DS5; -.
DR   PDBsum; 3DTJ; -.
DR   PDBsum; 3GV2; -.
DR   PDBsum; 3H47; -.
DR   PDBsum; 3H4E; -.
DR   PDBsum; 3L3U; -.
DR   PDBsum; 3L3V; -.
DR   PDBsum; 3LPT; -.
DR   PDBsum; 3LPU; -.
DR   PDBsum; 3LRY; -.
DR   PDBsum; 3MGE; -.
DR   PDBsum; 3NF6; -.
DR   PDBsum; 3NF7; -.
DR   PDBsum; 3NF8; -.
DR   PDBsum; 3NF9; -.
DR   PDBsum; 3NFA; -.
DR   PDBsum; 3P05; -.
DR   PDBsum; 3P0A; -.
DR   PDBsum; 3S85; -.
DR   PDBsum; 3WNE; -.
DR   PDBsum; 3WNF; -.
DR   PDBsum; 3WNG; -.
DR   PDBsum; 3WNH; -.
DR   PDBsum; 4AH9; -.
DR   PDBsum; 4AHR; -.
DR   PDBsum; 4AHS; -.
DR   PDBsum; 4AHT; -.
DR   PDBsum; 4AHU; -.
DR   PDBsum; 4AHV; -.
DR   PDBsum; 4COC; -.
DR   PDBsum; 4COP; -.
DR   PDBsum; 4DGA; -.
DR   PDBsum; 4DGE; -.
DR   PDBsum; 4DMN; -.
DR   PDBsum; 4E1M; -.
DR   PDBsum; 4E1N; -.
DR   PDBsum; 4E91; -.
DR   PDBsum; 4E92; -.
DR   PDBsum; 4GVM; -.
DR   PDBsum; 4GW6; -.
DR   PDBsum; 4ID1; -.
DR   PDBsum; 4IPY; -.
DR   PDBsum; 4JLH; -.
DR   PDBsum; 4JMU; -.
DR   PDBsum; 4LQW; -.
DR   PDBsum; 4NX4; -.
DR   PDBsum; 4O0J; -.
DR   PDBsum; 4O55; -.
DR   PDBsum; 4O5B; -.
DR   PDBsum; 4PHV; -.
DR   PDBsum; 4QNB; -.
DR   PDBsum; 4WYM; -.
DR   PDBsum; 5HVP; -.
DR   PDBsum; 9HVP; -.
DR   DisProt; DP00410; -.
DR   IntAct; P12497; 5.
DR   BindingDB; P12497; -.
DR   EvolutionaryTrace; P12497; -.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0072494; C:host multivesicular body; IEA:UniProtKB-SubCell.
DR   GO; GO:0019013; C:viral nucleocapsid; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004190; F:aspartic-type endopeptidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003887; F:DNA-directed DNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004533; F:exoribonuclease H activity; IEA:UniProtKB-EC.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0008289; F:lipid binding; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003964; F:RNA-directed DNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004523; F:RNA-DNA hybrid ribonuclease activity; IEA:InterPro.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0015074; P:DNA integration; IEA:UniProtKB-KW.
DR   GO; GO:0006310; P:DNA recombination; IEA:UniProtKB-KW.
DR   GO; GO:0075713; P:establishment of integrated proviral latency; IEA:UniProtKB-KW.
DR   GO; GO:0039651; P:induction by virus of host cysteine-type endopeptidase activity involved in apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0039657; P:suppression by virus of host gene expression; IEA:UniProtKB-KW.
DR   GO; GO:0046718; P:viral entry into host cell; IEA:UniProtKB-KW.
DR   GO; GO:0075732; P:viral penetration into host nucleus; IEA:UniProtKB-KW.
DR   GO; GO:0019076; P:viral release from host cell; IEA:UniProtKB-KW.
DR   Gene3D; 1.10.10.200; -; 1.
DR   Gene3D; 1.10.1200.30; -; 1.
DR   Gene3D; 1.10.150.90; -; 1.
DR   Gene3D; 1.10.375.10; -; 1.
DR   Gene3D; 2.30.30.10; -; 1.
DR   Gene3D; 2.40.70.10; -; 1.
DR   Gene3D; 3.30.420.10; -; 2.
DR   Gene3D; 4.10.60.10; -; 1.
DR   InterPro; IPR001969; Aspartic_peptidase_AS.
DR   InterPro; IPR000721; Gag_p24.
DR   InterPro; IPR001037; Integrase_C_retrovir.
DR   InterPro; IPR001584; Integrase_cat-core.
DR   InterPro; IPR017856; Integrase_Zn-bd_dom-like_N.
DR   InterPro; IPR003308; Integrase_Zn-bd_dom_N.
DR   InterPro; IPR000071; Lentvrl_matrix_N.
DR   InterPro; IPR012344; Matrix_HIV/RSV.
DR   InterPro; IPR018061; Pept_A2A_retrovirus_sg.
DR   InterPro; IPR001995; Peptidase_A2_cat.
DR   InterPro; IPR021109; Peptidase_aspartic_dom.
DR   InterPro; IPR008916; Retrov_capsid_C.
DR   InterPro; IPR008919; Retrov_capsid_N.
DR   InterPro; IPR010999; Retrovr_matrix.
DR   InterPro; IPR012337; RNaseH-like_dom.
DR   InterPro; IPR002156; RNaseH_domain.
DR   InterPro; IPR000477; RT_dom.
DR   InterPro; IPR010659; RVT_connect.
DR   InterPro; IPR010661; RVT_thumb.
DR   InterPro; IPR001878; Znf_CCHC.
DR   Pfam; PF00540; Gag_p17; 1.
DR   Pfam; PF00607; Gag_p24; 1.
DR   Pfam; PF00552; IN_DBD_C; 1.
DR   Pfam; PF02022; Integrase_Zn; 1.
DR   Pfam; PF00075; RNase_H; 1.
DR   Pfam; PF00665; rve; 1.
DR   Pfam; PF00077; RVP; 1.
DR   Pfam; PF00078; RVT_1; 1.
DR   Pfam; PF06815; RVT_connect; 1.
DR   Pfam; PF06817; RVT_thumb; 1.
DR   Pfam; PF00098; zf-CCHC; 2.
DR   PRINTS; PR00234; HIV1MATRIX.
DR   SMART; SM00343; ZnF_C2HC; 2.
DR   SUPFAM; SSF46919; SSF46919; 1.
DR   SUPFAM; SSF47353; SSF47353; 1.
DR   SUPFAM; SSF47836; SSF47836; 1.
DR   SUPFAM; SSF47943; SSF47943; 1.
DR   SUPFAM; SSF50122; SSF50122; 1.
DR   SUPFAM; SSF50630; SSF50630; 1.
DR   SUPFAM; SSF53098; SSF53098; 2.
DR   SUPFAM; SSF57756; SSF57756; 1.
DR   PROSITE; PS50175; ASP_PROT_RETROV; 1.
DR   PROSITE; PS00141; ASP_PROTEASE; 1.
DR   PROSITE; PS50994; INTEGRASE; 1.
DR   PROSITE; PS51027; INTEGRASE_DBD; 1.
DR   PROSITE; PS50879; RNASE_H; 1.
DR   PROSITE; PS50878; RT_POL; 1.
DR   PROSITE; PS50158; ZF_CCHC; 2.
DR   PROSITE; PS50876; ZF_INTEGRASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activation of host caspases by virus; AIDS;
KW   Aspartyl protease; Capsid protein; DNA integration; DNA recombination;
KW   DNA-binding; DNA-directed DNA polymerase; Endonuclease;
KW   Eukaryotic host gene expression shutoff by virus;
KW   Eukaryotic host translation shutoff by virus; Host cell membrane;
KW   Host cytoplasm; Host endosome; Host gene expression shutoff by virus;
KW   Host membrane; Host nucleus; Host-virus interaction; Hydrolase;
KW   Lipid-binding; Lipoprotein; Magnesium; Membrane; Metal-binding;
KW   Modulation of host cell apoptosis by virus; Multifunctional enzyme;
KW   Myristate; Nuclease; Nucleotidyltransferase; Phosphoprotein; Protease;
KW   Repeat; Ribosomal frameshifting; RNA-binding;
KW   RNA-directed DNA polymerase; Transferase; Viral genome integration;
KW   Viral nucleoprotein; Viral penetration into host nucleus; Virion;
KW   Virion maturation; Virus entry into host cell;
KW   Virus exit from host cell; Zinc; Zinc-finger.
FT   INIT_MET      1      1       Removed; by host. {ECO:0000250}.
FT   CHAIN         2   1435       Gag-Pol polyprotein.
FT                                /FTId=PRO_0000261276.
FT   CHAIN         2    132       Matrix protein p17. {ECO:0000250}.
FT                                /FTId=PRO_0000042394.
FT   CHAIN       133    363       Capsid protein p24. {ECO:0000250}.
FT                                /FTId=PRO_0000042395.
FT   PEPTIDE     364    377       Spacer peptide 1. {ECO:0000250}.
FT                                /FTId=PRO_0000042396.
FT   CHAIN       378    432       Nucleocapsid protein p7. {ECO:0000250}.
FT                                /FTId=PRO_0000042397.
FT   PEPTIDE     433    440       Transframe peptide. {ECO:0000255}.
FT                                /FTId=PRO_0000246725.
FT   CHAIN       441    488       p6-pol. {ECO:0000255}.
FT                                /FTId=PRO_0000042398.
FT   CHAIN       489    587       Protease. {ECO:0000250}.
FT                                /FTId=PRO_0000038660.
FT   CHAIN       588   1147       Reverse transcriptase/ribonuclease H.
FT                                {ECO:0000250}.
FT                                /FTId=PRO_0000042399.
FT   CHAIN       588   1027       p51 RT. {ECO:0000250}.
FT                                /FTId=PRO_0000042400.
FT   CHAIN      1028   1147       p15. {ECO:0000250}.
FT                                /FTId=PRO_0000042401.
FT   CHAIN      1148   1435       Integrase. {ECO:0000250}.
FT                                /FTId=PRO_0000042402.
FT   DOMAIN      508    577       Peptidase A2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00275}.
FT   DOMAIN      631    821       Reverse transcriptase.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00405}.
FT   DOMAIN     1021   1144       RNase H. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00408}.
FT   DOMAIN     1201   1351       Integrase catalytic.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00457}.
FT   ZN_FING     390    407       CCHC-type 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00047}.
FT   ZN_FING     411    428       CCHC-type 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00047}.
FT   ZN_FING    1150   1191       Integrase-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00450}.
FT   DNA_BIND   1370   1417       Integrase-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00506}.
FT   REGION        7     31       Interaction with Gp41.
FT                                {ECO:0000269|PubMed:8918455}.
FT   REGION        8     43       Interaction with host CALM1.
FT                                {ECO:0000250|UniProtKB:P04585}.
FT   REGION       12     19       Interaction with host AP3D1.
FT                                {ECO:0000269|PubMed:15766529}.
FT   REGION       14     33       Interaction with membrane
FT                                phosphatidylinositol 4,5-bisphosphate and
FT                                RNA. {ECO:0000269|PubMed:16840558}.
FT   REGION       73     77       Interaction with membrane
FT                                phosphatidylinositol 4,5-bisphosphate.
FT                                {ECO:0000269|PubMed:16840558}.
FT   REGION      189    227       Interaction with human PPIA/CYPA and
FT                                NUP153. {ECO:0000269|PubMed:19369352,
FT                                ECO:0000269|PubMed:24130490,
FT                                ECO:0000269|PubMed:8980234}.
FT   REGION      277    363       Dimerization/Multimerization of capsid
FT                                protein p24.
FT                                {ECO:0000250|UniProtKB:P04585}.
FT   REGION      489    493       Dimerization of protease.
FT                                {ECO:0000250|UniProtKB:P04585}.
FT   REGION      537    543       Dimerization of protease.
FT                                {ECO:0000250|UniProtKB:P04585}.
FT   REGION      576    588       Dimerization of protease.
FT                                {ECO:0000250|UniProtKB:P04585}.
FT   REGION      814    822       RT 'primer grip'. {ECO:0000250}.
FT   MOTIF        16     22       Nuclear export signal. {ECO:0000250}.
FT   MOTIF        26     32       Nuclear localization signal.
FT                                {ECO:0000250}.
FT   MOTIF       985   1001       Tryptophan repeat motif. {ECO:0000250}.
FT   ACT_SITE    513    513       For protease activity; shared with
FT                                dimeric partner. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10094}.
FT   METAL       697    697       Magnesium; catalytic; for reverse
FT                                transcriptase activity. {ECO:0000250}.
FT   METAL       772    772       Magnesium; catalytic; for reverse
FT                                transcriptase activity. {ECO:0000250}.
FT   METAL       773    773       Magnesium; catalytic; for reverse
FT                                transcriptase activity. {ECO:0000250}.
FT   METAL      1030   1030       Magnesium; catalytic; for RNase H
FT                                activity. {ECO:0000250}.
FT   METAL      1065   1065       Magnesium; catalytic; for RNase H
FT                                activity. {ECO:0000250}.
FT   METAL      1085   1085       Magnesium; catalytic; for RNase H
FT                                activity. {ECO:0000250}.
FT   METAL      1136   1136       Magnesium; catalytic; for RNase H
FT                                activity. {ECO:0000250}.
FT   METAL      1211   1211       Magnesium; catalytic; for integrase
FT                                activity.
FT   METAL      1263   1263       Magnesium; catalytic; for integrase
FT                                activity.
FT   METAL      1299   1299       Magnesium; catalytic; for integrase
FT                                activity. {ECO:0000250|UniProtKB:P04585}.
FT   SITE        132    133       Cleavage; by viral protease.
FT                                {ECO:0000250}.
FT   SITE        221    222       Cis/trans isomerization of proline
FT                                peptide bond; by human PPIA/CYPA.
FT                                {ECO:0000250}.
FT   SITE        363    364       Cleavage; by viral protease.
FT                                {ECO:0000250}.
FT   SITE        377    378       Cleavage; by viral protease.
FT                                {ECO:0000250}.
FT   SITE        432    433       Cleavage; by viral protease.
FT                                {ECO:0000255}.
FT   SITE        440    441       Cleavage; by viral protease.
FT                                {ECO:0000250}.
FT   SITE        488    489       Cleavage; by viral protease.
FT                                {ECO:0000250}.
FT   SITE        587    588       Cleavage; by viral protease.
FT                                {ECO:0000250}.
FT   SITE        988    988       Essential for RT p66/p51
FT                                heterodimerization. {ECO:0000250}.
FT   SITE       1001   1001       Essential for RT p66/p51
FT                                heterodimerization. {ECO:0000250}.
FT   SITE       1027   1028       Cleavage; by viral protease; partial.
FT                                {ECO:0000250}.
FT   SITE       1147   1148       Cleavage; by viral protease.
FT                                {ECO:0000250}.
FT   MOD_RES     132    132       Phosphotyrosine; by host. {ECO:0000250}.
FT   MOD_RES     148    148       Phosphoserine; by host MAPK1.
FT                                {ECO:0000269|PubMed:24509437}.
FT   LIPID         2      2       N-myristoyl glycine; by host.
FT                                {ECO:0000250}.
FT   MUTAGEN       9      9       S->A: Loss of ability to fuse with target
FT                                cell membranes and infect host cell.
FT                                {ECO:0000269|PubMed:19059618}.
FT   MUTAGEN      67     67       S->A: Loss of ability to fuse with target
FT                                cell membranes and infect host cell.
FT                                {ECO:0000269|PubMed:19059618}.
FT   MUTAGEN      72     72       S->A: Loss of ability to fuse with target
FT                                cell membranes and infect host cell.
FT                                {ECO:0000269|PubMed:19059618}.
FT   MUTAGEN      77     77       S->A: Loss of ability to fuse with target
FT                                cell membranes and infect host cell.
FT                                {ECO:0000269|PubMed:19059618}.
FT   STRAND        6      8       {ECO:0000244|PDB:1UPH}.
FT   HELIX        10     18       {ECO:0000244|PDB:4JMU}.
FT   STRAND       20     22       {ECO:0000244|PDB:4JMU}.
FT   STRAND       23     25       {ECO:0000244|PDB:1UPH}.
FT   HELIX        31     43       {ECO:0000244|PDB:4JMU}.
FT   HELIX        48     52       {ECO:0000244|PDB:4JMU}.
FT   HELIX        54     64       {ECO:0000244|PDB:4JMU}.
FT   HELIX        65     67       {ECO:0000244|PDB:4JMU}.
FT   TURN         68     70       {ECO:0000244|PDB:4JMU}.
FT   HELIX        73     90       {ECO:0000244|PDB:4JMU}.
FT   HELIX        97    108       {ECO:0000244|PDB:4JMU}.
FT   HELIX       109    112       {ECO:0000244|PDB:2H3Q}.
FT   HELIX       113    115       {ECO:0000244|PDB:2H3F}.
FT   TURN        117    119       {ECO:0000244|PDB:2H3F}.
FT   STRAND      134    136       {ECO:0000244|PDB:2XDE}.
FT   STRAND      138    140       {ECO:0000244|PDB:4E92}.
FT   STRAND      142    144       {ECO:0000244|PDB:2XDE}.
FT   HELIX       149    162       {ECO:0000244|PDB:2XDE}.
FT   HELIX       168    175       {ECO:0000244|PDB:2XDE}.
FT   TURN        176    178       {ECO:0000244|PDB:2XDE}.
FT   HELIX       181    189       {ECO:0000244|PDB:2XDE}.
FT   TURN        191    193       {ECO:0000244|PDB:4E92}.
FT   HELIX       195    215       {ECO:0000244|PDB:2XDE}.
FT   STRAND      217    219       {ECO:0000244|PDB:2XDE}.
FT   HELIX       233    236       {ECO:0000244|PDB:2XDE}.
FT   STRAND      239    241       {ECO:0000244|PDB:4NX4}.
FT   HELIX       243    251       {ECO:0000244|PDB:2XDE}.
FT   STRAND      252    254       {ECO:0000244|PDB:2XDE}.
FT   HELIX       258    277       {ECO:0000244|PDB:2XDE}.
FT   HELIX       282    284       {ECO:0000244|PDB:3DS4}.
FT   STRAND      289    291       {ECO:0000244|PDB:3DS5}.
FT   HELIX       293    306       {ECO:0000244|PDB:3DS4}.
FT   TURN        308    310       {ECO:0000244|PDB:4QNB}.
FT   HELIX       311    324       {ECO:0000244|PDB:3DS4}.
FT   HELIX       328    337       {ECO:0000244|PDB:3DS4}.
FT   HELIX       343    350       {ECO:0000244|PDB:3DS4}.
FT   TURN        351    354       {ECO:0000244|PDB:3DS0}.
FT   HELIX       356    361       {ECO:0000244|PDB:4IPY}.
FT   STRAND      380    383       {ECO:0000244|PDB:2M3Z}.
FT   STRAND      385    389       {ECO:0000244|PDB:2M3Z}.
FT   STRAND      393    395       {ECO:0000244|PDB:2M3Z}.
FT   TURN        402    404       {ECO:0000244|PDB:2M3Z}.
FT   STRAND      414    416       {ECO:0000244|PDB:2M3Z}.
FT   STRAND      419    421       {ECO:0000244|PDB:2M3Z}.
FT   TURN        423    425       {ECO:0000244|PDB:2M3Z}.
FT   STRAND      490    495       {ECO:0000244|PDB:5HVP}.
FT   STRAND      498    503       {ECO:0000244|PDB:5HVP}.
FT   STRAND      506    512       {ECO:0000244|PDB:5HVP}.
FT   STRAND      517    523       {ECO:0000244|PDB:5HVP}.
FT   STRAND      531    537       {ECO:0000244|PDB:5HVP}.
FT   STRAND      540    554       {ECO:0000244|PDB:5HVP}.
FT   STRAND      557    567       {ECO:0000244|PDB:5HVP}.
FT   HELIX       575    578       {ECO:0000244|PDB:5HVP}.
FT   HELIX       579    581       {ECO:0000244|PDB:5HVP}.
FT   STRAND      584    586       {ECO:0000244|PDB:5HVP}.
FT   HELIX      1151   1162       {ECO:0000244|PDB:1K6Y}.
FT   HELIX      1166   1173       {ECO:0000244|PDB:1K6Y}.
FT   HELIX      1177   1186       {ECO:0000244|PDB:1K6Y}.
FT   HELIX      1188   1191       {ECO:0000244|PDB:1WJB}.
FT   HELIX      1204   1206       {ECO:0000244|PDB:3WNE}.
FT   STRAND     1207   1215       {ECO:0000244|PDB:3WNF}.
FT   STRAND     1218   1225       {ECO:0000244|PDB:3WNF}.
FT   TURN       1226   1228       {ECO:0000244|PDB:3WNF}.
FT   STRAND     1231   1238       {ECO:0000244|PDB:3WNF}.
FT   HELIX      1241   1254       {ECO:0000244|PDB:3WNF}.
FT   STRAND     1259   1261       {ECO:0000244|PDB:3WNF}.
FT   HELIX      1266   1268       {ECO:0000244|PDB:3WNF}.
FT   HELIX      1271   1280       {ECO:0000244|PDB:3WNF}.
FT   STRAND     1283   1285       {ECO:0000244|PDB:3AV9}.
FT   HELIX      1292   1295       {ECO:0000244|PDB:1B9F}.
FT   HELIX      1300   1312       {ECO:0000244|PDB:3WNF}.
FT   HELIX      1313   1315       {ECO:0000244|PDB:3WNF}.
FT   STRAND     1316   1318       {ECO:0000244|PDB:1B9D}.
FT   HELIX      1319   1332       {ECO:0000244|PDB:3WNF}.
FT   HELIX      1335   1337       {ECO:0000244|PDB:1BIS}.
FT   STRAND     1338   1340       {ECO:0000244|PDB:1BIS}.
FT   HELIX      1343   1355       {ECO:0000244|PDB:3WNF}.
SQ   SEQUENCE   1435 AA;  161789 MW;  798E74FD27C21244 CRC64;
     MGARASVLSG GELDKWEKIR LRPGGKKQYK LKHIVWASRE LERFAVNPGL LETSEGCRQI
     LGQLQPSLQT GSEELRSLYN TIAVLYCVHQ RIDVKDTKEA LDKIEEEQNK SKKKAQQAAA
     DTGNNSQVSQ NYPIVQNLQG QMVHQAISPR TLNAWVKVVE EKAFSPEVIP MFSALSEGAT
     PQDLNTMLNT VGGHQAAMQM LKETINEEAA EWDRLHPVHA GPIAPGQMRE PRGSDIAGTT
     STLQEQIGWM THNPPIPVGE IYKRWIILGL NKIVRMYSPT SILDIRQGPK EPFRDYVDRF
     YKTLRAEQAS QEVKNWMTET LLVQNANPDC KTILKALGPG ATLEEMMTAC QGVGGPGHKA
     RVLAEAMSQV TNPATIMIQK GNFRNQRKTV KCFNCGKEGH IAKNCRAPRK KGCWKCGKEG
     HQMKDCTERQ ANFLREDLAF PQGKAREFSS EQTRANSPTR RELQVWGRDN NSLSEAGADR
     QGTVSFSFPQ ITLWQRPLVT IKIGGQLKEA LLDTGADDTV LEEMNLPGRW KPKMIGGIGG
     FIKVRQYDQI LIEICGHKAI GTVLVGPTPV NIIGRNLLTQ IGCTLNFPIS PIETVPVKLK
     PGMDGPKVKQ WPLTEEKIKA LVEICTEMEK EGKISKIGPE NPYNTPVFAI KKKDSTKWRK
     LVDFRELNKR TQDFWEVQLG IPHPAGLKQK KSVTVLDVGD AYFSVPLDKD FRKYTAFTIP
     SINNETPGIR YQYNVLPQGW KGSPAIFQCS MTKILEPFRK QNPDIVIYQY MDDLYVGSDL
     EIGQHRTKIE ELRQHLLRWG FTTPDKKHQK EPPFLWMGYE LHPDKWTVQP IVLPEKDSWT
     VNDIQKLVGK LNWASQIYAG IKVRQLCKLL RGTKALTEVV PLTEEAELEL AENREILKEP
     VHGVYYDPSK DLIAEIQKQG QGQWTYQIYQ EPFKNLKTGK YARMKGAHTN DVKQLTEAVQ
     KIATESIVIW GKTPKFKLPI QKETWEAWWT EYWQATWIPE WEFVNTPPLV KLWYQLEKEP
     IIGAETFYVD GAANRETKLG KAGYVTDRGR QKVVPLTDTT NQKTELQAIH LALQDSGLEV
     NIVTDSQYAL GIIQAQPDKS ESELVSQIIE QLIKKEKVYL AWVPAHKGIG GNEQVDGLVS
     AGIRKVLFLD GIDKAQEEHE KYHSNWRAMA SDFNLPPVVA KEIVASCDKC QLKGEAMHGQ
     VDCSPGIWQL DCTHLEGKVI LVAVHVASGY IEAEVIPAET GQETAYFLLK LAGRWPVKTV
     HTDNGSNFTS TTVKAACWWA GIKQEFGIPY NPQSQGVIES MNKELKKIIG QVRDQAEHLK
     TAVQMAVFIH NFKRKGGIGG YSAGERIVDI IATDIQTKEL QKQITKIQNF RVYYRDSRDP
     VWKGPAKLLW KGEGAVVIQD NSDIKVVPRR KAKIIRDYGK QMAGDDCVAS RQDED
//
